Share Twitter LinkedIn Facebook Email Jon Eckard, PhD, TYME Inc., shares Trial Designed to Target Unique Tumor Biology Most cancer therapies come with side-effects at Annual Meeting 2018.
FDA Accelerates Approval of Afamitresgene Autoleucel for Advanced Synovial Sarcoma Sarcoma 2 Mins Read
Exploring Cabozantinib Plus Nivolumab: A Breakthrough in Advanced Angiosarcoma – An Interview with Dr. Gary Schwartz Sarcoma 1 Min Read